N4 Pharma shares jump on latest Nuvec developments
15th Feb 2024 13:17
(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.
Read moreN4 Pharma's Nuvec granted patent in India
19th Jan 2024 13:00
(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.
Read moreN4 Pharma subsidiary agrees work programme for glaucoma treatment
16th Jan 2024 14:05
(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.
Read moreN4 Pharma reports progress in Nuvec clinical research
8th Jan 2024 12:30
(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.
Read moreN4 Pharma upbeat on recent Nuvec developments
18th Dec 2023 11:17
(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
Read moreN4 Pharma posts optimistic Nuvec research update
7th Dec 2023 13:20
(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA research efforts on Thursday.
Read moreN4 Pharma picks up controlling interest in Nanogenics
28th Sep 2023 13:28
(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.
Read moreN4 Pharma reports progress with siRNA work
18th Apr 2023 13:13
(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.
Read moreN4 Pharma shares tumble following placing, broker offer announcement
18th Nov 2022 08:11
(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.
Read moreN4 Pharma reports success in recent 'Nuvec' testing
4th Oct 2022 13:32
(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.
Read moreN4 Pharma reduces losses as Nuvec development continues
29th Sep 2022 12:11
(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.
Read moreN4 Pharma upbeat on latest tumour suppression study data
15th Jul 2022 13:23
(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.
Read moreN4 Pharma outlines work plan after 'encouraging' data
25th Jan 2022 14:50
(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.
Read moreN4 upbeat on cancer treatment progress, vaccine disappoints
13th Dec 2021 14:56
(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.
Read moreN4 Pharma granted Europe patent with China equivalent on its way
1st Oct 2021 09:35
(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.
Read more